Amid Chase for Illumina, Roche Posts Q1 MDx Sales Jump as Applied Science Drops | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent year over year, while its sales for microarrays and genomic sequencing products dropped sharply.

The Swiss pharmaceuticals, diagnostics, and research products giant also issued another statement saying that its $51-per-share offer to acquire Illumina is "full, fair, and extremely attractive by every conceivable metric."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."